Proteros announces New Supervisory Board Appointments: Chairman David Lemus and Deputy Chairman Prof. Rainer Metternich
Mr. David Lemus will assume the role of Chairman for the Board and will lead the Business and Corporate Development committee to identify opportunities for expanding Proteros services and establishing strategic collaborations. Mr. Lemus most recently served as a Member of the Management Board, Executive Vice President and Chief Financial Officer of MorphoSys AG. After taking the Company public in 1999, Mr. Lemus held responsibility for a variety of areas including corporate development, corporate communications, technical operations and legal. He helped build MorphoSys over the past thirteen years and his contributions were central in the rapid growth of the Company. Mr. Lemus joined MorphoSys in 1998 from F.Hoffmann-La Roche, where he served as a Controller and Operations Manager of 90 pharmaceutical markets. Prior to this position, he served as a Treasurer of Lindt & Sprungli in Zurich, Switzerland and worked in treasury management at Electrolux AB. Mr. Lemus joined MorphoSys AG in February 1998. Mr. Lemus is a Certified Public Accountant in the U.S.A. and holds an M.S. from the M.I.T. Sloan School of Management.
Prof. Dr. Rainer Metternich is newly appointed as Deputy Chairman of the Board. In addition to his responsibility as Deputy Chair of the Supervisory Board, Prof. Metternich will head the R&D/Lead Discovery committee at Proteros to guide the company as it continues to grow and develop its integrated Lead Discovery services offering. Prof. Metternich is a Senior Research Executive with over 20 years leadership experience at global pharmaceutical companies. He is currently acting Managing Director, Chief Business Officer and Chief Operating Officer of caprotec bioanalytics GmbH. He was previously Vice President and Basic Research Site Head at Merck & Co in West Point, PA, USA. Prior to that position, he was Executive Vice President and Member of the Executive Committee at Schering AG in Berlin, and, before this, was Global Senior Chemistry Expert at Novartis in Basel, Switzerland. He earned his doctorate degree in organic chemistry from the University at Marburg, Germany with Professor Reinhard W. Hoffmann, was a postdoctoral fellow at Harvard University with Professor David A. Evans and spent a Sabbatical at the University of California, Berkeley with Professor Paul A. Bartlett. He is on the Editorial Boards of several leading scientific journals and a member of several Scientific Advisory Boards of academic, private and non-profit research organizations.
Torsten Neuefeind, CEO and founder of Proteros, said “It is important that we anticipate our customer’s needs and have established best practice throughout the organization so that we can continue our rapid growth and maintain our high quality reputation. We are very honoured to have such experienced professionals assist in actively guiding Proteros as we continue to grow our integrated drug discovery services.”
Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery. Proteros uses its technical expertise, industrial processes and unique technologies for crystallography, kinetic and thermodynamic profiling and fragment-based lead generation incorporating protein structure inspired compound and fragment libraries. Proteros complements its clients’ internal capabilities with external expertise and access to flexible resources. Proteros currently provides services to more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia. Proteros US, Inc. is a wholly owned subsidiary of Proteros established to serve the growing customer base in North America.
Proteros biostructures GmbH
Kurt Herrenknecht, Ph.D.
Am Klopferspitz 19
Phone: +49 (0) 89 7007 61 0
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Proteros announces New Supervisory Board Appointments: Chairman David Lemus and Deputy Chairman Prof. Rainer Metternich here
News-ID: 174364 • Views: 2237
More Releases from Proteros biostructures GmbH
PROTEROS ANNOUNCES SUCCESSFUL CLOSE OF FINANCING ROUND
Largest-ever Financing allows for Expansion of Drug Discovery Capabilities MARTINSRIED, GERMANY (August 6th, 2012) – Proteros biostructures GmbH (‘Proteros’) announced today that it had successfully closed a financing round of five million Euros to fund the continued expansion and growth of the company. The financing round was led by BayBG, a key equity investor for Proteros. The financing round is the third and largest investment into the firm since the inception
Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration
Martinsried (Germany), April 16, 2012. Proteros biostructures GmbH today announced that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology. Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry
Proteros announces the appointment of Dr. Klaus Hinterding as Chief Scientific O …
Martinsried, Germany, February 9, 2012. Proteros biostructures GmbH (Proteros) announced today that Dr. Klaus Hinterding, formerly at Hoffmann-La Roche Ltd. (Roche), has joined the company as Chief Scientific Officer and member of the management board. Dr. Hinterding brings to Proteros considerable pharmaceutical industry experience that spans early research through to clinical development in various therapeutic areas. At Novartis, his research contributed to the understanding of the mode-of-action of GilenyaTM, licensed for
Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global …
Martinsried Jan 09, 2012. Janssen Research & Development, a division of Janssen Pharmaceutica NV (“Janssen”) and Proteros biostructures GmbH (“Proteros”) today announced they have entered into a long-term global service agreement granting Janssen privileged access to Proteros portfolio of discovery technologies and services. Under the agreement Janssen will have broad access to Proteros’ drug discovery technologies, including structural biology, biophysical screening and profiling service, novel fragment libraries, medicinal chemistry expertise and
More Releases for Lemus
NARI Chicago remodelers volunteer to create new kitchen in Schaumburg foster hom …
They say if you can’t stand the heat, get out of the kitchen. But a group of remodelers from the Greater Chicagoland Chapter of the National Association of the Remodeling Industry (NARI) didn’t back down from the challenge of creating a new kitchen for a foster parent whose Schaumburg townhome was damaged by fire last year. Thanks to their volunteered labor and the plentiful materials donated by generous suppliers, Rich